• 2015.06

    Hangzhou Sumgen Biotech Co., Ltd.was Founded

  • 2015.12

    Sumgen Biotech applied for the first invention patent

  • 2016.10

    Beijing R&D Center,
    Sumgen Monoclonal Antibody (Beijing) Biotech Co., Ltd. was Built

  • 2017.03

    Sumgen Biotech Completed Angel Investment

  • 2018.06

    IND Application of the First R&D Project of
    Sumgen Biotech was Filed to CDE

  • 2018.09

    The First Independent R&D Project of
    Sumgen Biotech was Granted Clinical Trial Permission by CDE

  • 2019.01

    Sumgen Biotech Completed Series A+ Funding

  • 2019.12

    Recognized as National High-tech Enterprises;
    Designated as Hangzhou Patent Demonstration Enterprise

  • 2020.03

    Hangzhou Sumgen Biotech Co., Ltd. and CNBG Set Up the Joint Venture
    CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. (“CNBG Sumgen”)

  • 2020.09

    The Series B Funding (RMB 220 million) was completed

  • 2020.11

    Two Projects were Approved for Clinical Trials in China and the United States
    Honored as One of China's Top 50 Innovative Enterprises in the Bio-Pharmaceutical Industry in 2020

  • 2021.01

    The First Subject was Enrolled in the Clinical Trial of SG404

  • 2021.02

    The Innovative Drug SG404 was Approved by the US FDA


The company has deployed a series of antibody drugs in the tumor field.

Discover More


A world-leading antibody R&D and industrialization platform.

Discover More

Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044